{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"15"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"25"}],"units":"Participants"}],"description":"Responder is defined as subject with a decrease greater than or equal to 25% in area under the curve for glucose on 2-hour oral glucose test from baseline to week 24 or last visit, for Cushing's patients with type-2 diabetes mellitus/impaired glucose tolerance.","groups":[{"description":"Mifepristone was administered at doses of 300-1200 mg daily.","id":"OG000","title":"Mifepristone"}],"paramType":"NUMBER","populationDescription":"Patients with at least 30 days of dosing.","reportingStatus":"POSTED","timeFrame":"Baseline to Week 24","title":"Improvement in Diabetes and/or Glucose Intolerance.","type":"PRIMARY","unitOfMeasure":"participants"}